113.38
-0.42 (-0.37%)
| Previous Close | 113.80 |
| Open | 113.50 |
| Volume | 58,748 |
| Avg. Volume (3M) | 119,072 |
| Market Cap | 2,142,360,448 |
| Price / Earnings (TTM) | 45.53 |
| Price / Earnings (Forward) | 21.37 |
| Price / Sales | 14.97 |
| Price / Book | 2.79 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 - 3 Mar 2025 |
| Profit Margin | 29.68% |
| Operating Margin (TTM) | 21.14% |
| Diluted EPS (TTM) | 2.49 |
| Quarterly Revenue Growth (YOY) | 57.60% |
| Total Debt/Equity (MRQ) | 0.88% |
| Current Ratio (MRQ) | 12.49 |
| Operating Cash Flow (TTM) | 76.64 M |
| Levered Free Cash Flow (TTM) | 16.96 M |
| Return on Assets (TTM) | 1.30% |
| Return on Equity (TTM) | 6.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Ligand Pharmaceuticals Incorpor | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.13 |
|
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.89% |
| % Held by Institutions | 100.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Congress Asset Management Co | 30 Sep 2024 | 604,038 |
| Ashford Capital Management Inc | 30 Sep 2024 | 310,407 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 160.00 (Barclays, 41.12%) | Buy |
| Median | 147.00 (29.65%) | |
| Low | 135.00 (Benchmark, 19.07%) | Buy |
| Average | 148.40 (30.89%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 119.80 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Benchmark | 23 Dec 2024 | 135.00 (19.07%) | Buy | 113.80 |
| 08 Nov 2024 | 135.00 (19.07%) | Buy | 121.25 | |
| Barclays | 16 Dec 2024 | 160.00 (41.12%) | Buy | 122.34 |
| 08 Nov 2024 | 150.00 (32.30%) | Buy | 121.25 | |
| RBC Capital | 11 Dec 2024 | 143.00 (26.12%) | Buy | 120.36 |
| 12 Nov 2024 | 140.00 (23.48%) | Buy | 120.74 | |
| HC Wainwright & Co. | 08 Nov 2024 | 157.00 (38.47%) | Buy | 121.25 |
| 31 Oct 2024 | 157.00 (38.47%) | Buy | 105.70 | |
| Oppenheimer | 08 Nov 2024 | 147.00 (29.65%) | Buy | 121.25 |
| 03 Oct 2024 | 135.00 (19.07%) | Buy | 102.24 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Dec 2024 | Announcement | Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance |
| 14 Nov 2024 | Announcement | Ligand to Present at Stifel 2024 Healthcare Conference |
| 07 Nov 2024 | Announcement | Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance |
| 01 Nov 2024 | Announcement | Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston |
| 23 Oct 2024 | Announcement | Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 |
| 17 Oct 2024 | Announcement | Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |